Amphastar Pharmaceuticals, Inc. — Director's Dealing 2021

Feb 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Amphastar Pharmaceuticals, Inc. (AMPH)
CIK: 0001297184
Period of Report: 2021-02-01

Reporting Person: Zhang Jack Y. (Director, CEO & Chief Scientific Officer, 10% Owner)
Reporting Person: Luo Mary Z. (Director, COO,Chief Scientist & Chairman, 10% Owner)
Reporting Person: Applied Physics & Chemistry Laboratories, Inc. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-01	Common Stock	S	24114	$18.2931	Disposed	7003565	Indirect
2021-02-02	Common Stock	S	13817	$18.6597	Disposed	6989748	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2246988	Direct
Common Stock	1449961	Indirect
Common Stock	5000	Indirect

Footnotes

F1: The sales reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4).

F3: The shares are held of record by Applied Physics & Chemistry Laboratories, Inc., of which the reporting persons and The Bill Luobei Zhang 2004 Irrevocable Trust (the "BLZ Trust") are the sole owners.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.52 to $18.78, inclusive.

F5: The securities are held of record by Mary Z. Luo. The reporting persons are husband and wife.

F6: The shares are held of record in an account for the benefit of the reporting persons' son. The reporting persons disclaim beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.